Hepatitis Monthly

Published by: Kowsar

Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Bariatric Patients: Tehran Obesity Treatment Study (TOTS)

Maryam Barzin 1 , Mohammad Ali Kalantar Motamedi 1 , Alireza Khalaj 2 , Sara Serahati 1 , Davood Khalili 3 , Arman Morakabati 4 , Majid Valizadeh 1 , Fereidoun Azizi 5 , Farhad Hosseinpanah 1 and Nasser Rakhshani 4 , *
Authors Information
1 Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Tehran Obesity Treatment Center, Department of Surgery, Faculty of Medicine, Shahed University, Tehran, Iran
3 Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Gastrointestinal and Liver Disease Research Center, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
5 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • Hepatitis Monthly: May 2018, 18 (5); e64380
  • Published Online: May 12, 2018
  • Article Type: Research Article
  • Received: November 24, 2017
  • Revised: April 25, 2018
  • Accepted: April 28, 2018
  • DOI: 10.5812/hepatmon.64380

To Cite: Barzin M, Kalantar Motamedi M A, Khalaj A, Serahati S, Khalili D, et al. Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Bariatric Patients: Tehran Obesity Treatment Study (TOTS), Hepat Mon. 2018 ;18(5):e64380. doi: 10.5812/hepatmon.64380.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
References
  • 1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. [PubMed: 21623852].
  • 2. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524-530 e1. quiz e60. doi: 10.1016/j.cgh.2011.03.020. [PubMed: 21440669].
  • 3. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75(10):721-8. doi: 10.3949/ccjm.75.10.721. [PubMed: 18939388].
  • 4. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9-19. [PubMed: 19240815]. [PubMed Central: PMC2633261].
  • 5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-23. doi: 10.1002/hep.25762. [PubMed: 22488764].
  • 6. Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12(3). e0173499. doi: 10.1371/journal.pone.0173499. [PubMed: 28346543]. [PubMed Central: PMC5367688].
  • 7. Haflidadottir S, Jonasson JG, Norland H, Einarsdottir SO, Kleiner DE, Lund SH, et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol. 2014;14:166. doi: 10.1186/1471-230X-14-166. [PubMed: 25260964]. [PubMed Central: PMC4182763].
  • 8. Seki Y, Kakizaki S, Horiguchi N, Hashizume H, Tojima H, Yamazaki Y, et al. Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery. J Gastroenterol. 2016;51(3):281-9. doi: 10.1007/s00535-015-1114-8. [PubMed: 26314837].
  • 9. Morita S, Neto Dde S, Morita FH, Morita NK, Lobo SM. Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery. Obes Surg. 2015;25(12):2335-43. doi: 10.1007/s11695-015-1696-5. [PubMed: 25920616].
  • 10. Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, et al. Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran. Iran J Public Health. 2014;43(9):1275-83. [PubMed: 26175982]. [PubMed Central: PMC4500430].
  • 11. Pirvulescu I, Gheorghe L, Csiki I, Becheanu G, Dumbrava M, Fica S, et al. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery. Chirurgia (Bucur). 2012;107(6):772-9. [PubMed: 23294957].
  • 12. Petrick A, Benotti P, Wood GC, Still CD, Strodel WE, Gabrielsen J, et al. Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients. Obes Surg. 2015;25(12):2368-75. doi: 10.1007/s11695-015-1707-6. [PubMed: 26003548]. [PubMed Central: PMC4917009].
  • 13. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54. doi: 10.1002/hep.21496. [PubMed: 17393509].
  • 14. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25. doi: 10.1002/hep.21178. [PubMed: 16729309].
  • 15. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486-501. doi: 10.1002/hep.29302. [PubMed: 28586172].
  • 16. Simo KA, McKillop IH, McMillan MT, Ahrens WA, Walters AL, Thompson KJ, et al. Does a calculated "NAFLD fibrosis score" reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes Surg. 2014;24(1):15-21. doi: 10.1007/s11695-013-1044-6. [PubMed: 23934335].
  • 17. Sherif ZA, Saeed A, Ghavimi S, Nouraie SM, Laiyemo AO, Brim H, et al. Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci. 2016;61(5):1214-25. doi: 10.1007/s10620-016-4143-0. [PubMed: 27038448]. [PubMed Central: PMC4838529].
  • 18. Barzin M, Hosseinpanah F, Motamedi MA, Shapoori P, Arian P, Daneshpour MA, et al. Bariatric Surgery for Morbid Obesity: Tehran Obesity Treatment Study (TOTS) Rationale and Study Design. JMIR Res Protoc. 2016;5(1). e8. doi: 10.2196/resprot.5214. [PubMed: 26792554]. [PubMed Central: PMC4740496].
  • 19. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21. doi: 10.1002/hep.20701. [PubMed: 15915461].
  • 20. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644. [PubMed: 19805654].
  • 21. Hosseinpanah F, Borzooei S, Barzin M, Farshadi M, Sarvghadi F, Azizi F. Diagnostic values of metabolic syndrome definitions for detection of insulin resistance: Tehran Lipid and Glucose Study (TLGS). Arch Iran Med. 2012;15(10):606-10. [PubMed: 23020535].
  • 22. Esteghamati A, Etemad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Noshad S, et al. Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005-2011. Diabetes Res Clin Pract. 2014;103(2):319-27. doi: 10.1016/j.diabres.2013.12.034. [PubMed: 24447808].
  • 23. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617-49. doi: 10.3109/07853890.2010.518623. [PubMed: 21039302].
  • 24. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431. [PubMed: 26707365].
  • 25. Subichin M, Clanton J, Makuszewski M, Bohon A, Zografakis JG, Dan A. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11(1):137-41. doi: 10.1016/j.soard.2014.06.015. [PubMed: 25701959].
  • 26. Younossi Z, Henry L. Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. Gastroenterology. 2016;150(8):1778-85. doi: 10.1053/j.gastro.2016.03.005. [PubMed: 26980624].
  • 27. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20(2):205-14. doi: 10.1016/j.cld.2015.10.001. [PubMed: 27063264].
  • 28. Kroh M, Liu R, Chand B. Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients. Surg Endosc. 2007;21(11):1957-60. doi: 10.1007/s00464-007-9351-4. [PubMed: 17479322].
  • 29. Praveenraj P, Gomes RM, Kumar S, Karthikeyan P, Shankar A, Parthasarathi R, et al. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery. Obes Surg. 2015;25(11):2078-87. doi: 10.1007/s11695-015-1655-1. [PubMed: 25835982].
  • 30. Liew PL, Lee WJ, Wang W, Lee YC, Chen WY, Fang CL, et al. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obes Surg. 2008;18(7):847-53. doi: 10.1007/s11695-007-9355-0. [PubMed: 18459024].
  • 31. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913-24. doi: 10.1002/hep.23784. [PubMed: 20648476]. [PubMed Central: PMC3070295].
  • 32. Qureshi K, Abrams GA. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome. Clin Obes. 2016;6(2):117-23. doi: 10.1111/cob.12132. [PubMed: 26856683].
  • 33. Le D, Marks D, Lyle E, Corless CL, Diggs BS, Jobe BA, et al. Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients. Surg Endosc. 2007;21(9):1593-9. doi: 10.1007/s00464-006-9185-5. [PubMed: 17294310].
  • 34. Rodriguez-Gallego E, Guirro M, Riera-Borrull M, Hernandez-Aguilera A, Marine-Casado R, Fernandez-Arroyo S, et al. Mapping of the circulating metabolome reveals alpha-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease. Int J Obes (Lond). 2015;39(2):279-87. doi: 10.1038/ijo.2014.53. [PubMed: 24675715].
  • 35. Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res. 2014;44(8):854-62. doi: 10.1111/hepr.12197. [PubMed: 23834322].
  • 36. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. doi: 10.1002/hep.29367. [PubMed: 28714183].
  • 37. Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol. 2010;52(4):579-85. doi: 10.1016/j.jhep.2010.01.008. [PubMed: 20185194].
  • 38. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-50. doi: 10.1053/gast.2002.35354. [PubMed: 12198701].
  • 39. Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007;102(12):2716-7. doi: 10.1111/j.1572-0241.2007.01520.x. [PubMed: 18042105].
  • 40. de Moura Almeida A, Cotrim HP, Barbosa DB, de Athayde LG, Santos AS, Bitencourt AG, et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol. 2008;14(9):1415-8. doi: 10.3748/wjg.14.1315. [PubMed: 18322958]. [PubMed Central: PMC2693692].
  • 41. Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013;11(9):1201-4. doi: 10.1016/j.cgh.2012.12.031. [PubMed: 23353640].
  • 42. De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, et al. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Frontline Gastroenterol. 2018;9(2):115-21. doi: 10.1136/flgastro-2017-100865. [PubMed: 29588839]. [PubMed Central: PMC5868450].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments